Honasa Consumer calls off proposed Fluence Pharma acquisition
HONASA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Smallcap 250 and 2.0 pts less than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Honasa Consumer Limited has called off its proposed acquisition of a 58 percent equity stake in Fluence Pharma Private Limited. The deal was terminated on August 25, 2026 due to non-fulfilment of closing conditions under the Share Purchase Agreement signed earlier. The company had first informed exchanges about the proposed acquisition on June 23, 2026. Honasa stated it remains committed to its nutraceutical strategy and will keep evaluating both organic and inorganic growth opportunities in the category.
Removes a near-term inorganic growth lever in nutraceuticals; may be neutral to mildly negative near term but company signals continued M and A interest.